The mouse adenocarcinoma of the colon (MAC) series of transplantable tumours has been used in a variety of chemotherapy studies. They have many characteristics in common with human large bowel cancer (Ball & Double, 1975; and they are easy to maintain in serial passage. The rationale behind their development was the provision of a range of transplantable lines showing a spectrum of histology and chemosensitivity similar to that seen in the clinic. In man the histological appearance of colon carcinomas varies considerably with most being well-or moderately-differentiated tubular adenocarcinomas and only about 20% being poorly differentiated or anaplastic. Much of the previous work with the MAC tumours has concentrated on the moderately-differentiated lines (Double & Carter, 1978; Double & Cifuentes de Castro, 1978; Bibby et al., 1981) . In the present investigation we present chemotherapy screening data from a mucin producing tumour (MAC 30T). This expands our panel of MAC tumours to include lines with different growth rates and with histology ranging from anaplastic to well-differentiated.
Pure-strain female NMRI mice (age 6-8 weeks) from our inbred colony were used. Animals were fed diet 86 (James Burnhill & Sons, Cleckheaton, England) and water ad libitum. The development of several transplantable adenocarcinomas of the large bowel from primary tumours induced by prolonged administration of 1,2-dimethyl hydrazine has been described elsewhere .
MAC 30T (previously designated MAC 30) was first briefly described by Cowen et al. (1980) B.J.C.
F
-1 x 2 mm in size. Fragments were implanted into the flank using a trocar. Positive takes can only be identified 2-3 weeks after transplantation. All histological specimens were fixed in 10% buffered formalin and sections were stained with haematoxylin and eosin, periodic acid Schiff (PAS) or Alcian Blue (AB).
Fourteen days after transplantation (the shortest time at which accurate measurements could be made) tumour-bearing mice were allocated into groups of 8 by restricted randomisation. (These tumours exhibit a take rate of almost 100%). Chemotherapy commenced on Day 0 and its effects were assessed by serial, twice weekly, twodimensional caliper measurements. Tumour volume was calculated from the formula a2 x b/2 where a is the smaller diameter and b is the larger (Geran et al., 1972) . Tumour volumes were normalised with respect to their starting volumes and semi-log plots were drawn of relative tumour volume (RTV) against time. Slopes of the growth curves were calculated and the best lines of fit were drawn. The control plot was constructed from data pooled from the whole series of experiments. In the treated group the best lines of fit were drawn on the graph from the points after treatment where exponential regrowth commenced. Fractional volume reduction and specific growth delay were also calculated for each drug at maximum tolerated dose as Steel et al., (1983) Time (days) Figure 3 Effects of Treosulfan on MAC 30/T (O> 2gkg-', * 3gkg-, -seen with Aclacinomycin A at a dose level of 20 mg kg-1. If anti-tumour effect is measured as specific growth delay or fractional volume reduction instead of growth delay a similar picture is obtained (Table I) . The results have also been presented as specific growth delay and fractional volume reduction. This does not alter the ranking of compounds in order of anti-tumour activity as one is calculated from the other but as Steel et al. (1983) point out these methods permit comparison of activity to be made between systems with differing growth rates. It will be adopted in our future studies on tumour systems where growth can be realistically followed.
It is debatable (Cowen et al., 1982) whether murine transplantable tumours or transplantable tumour lines of any other species of laboratory animals can be a model for human cancer or whether it is necessary to use tumours from a similar tissue of origin to that of the human tumour. In the meantime, chemotherapeutic drugs will still need initial screening and evaluation in animal models and it is considered that the enlarged MAC series would be eminently suited to such programes, particularly as it is likely that tumour architecture may influence pharmacokinetics, drug disposition and bioavailability at the cellular level. 
